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Abstract 
Possible regulation of L-type Ca 2+ channels by tyrosine kinase was examined in freshly isolated uterine smooth muscle cells obtained 
from late pregnant (18-19 day) rat, using whole-cell voltage clamp. Bath application of genistein, an inhibitor of tyrosine kinase, 
decreased L-type Ca 2+ current (Ic~L)) dose-dependently. The maximal inhibition of /Co(L) was 46% and the concentration for 
half-maximal inhibition (IC50) was 50 /xM (at a holding potential of -60  mV). The effect of genistein was reversible. Daidzein, an 
inactive analog of genistein, had no inhibitory effect on /Ca(L) at concentrations a  high as 300 ~M. The steady-state inactivation curve 
for IC~L) was shifted to the left by genistein (15 mV at 100 tzM), whereas the activation curve was not affected, suggesting that genistein 
exerts a voltage-dependent block. These results suggest hat the L-type Ca 2+ channels in myometrial cells may be modulated by 
endogenous tyrosine kinase, i.e., they are in a tonically stimulated state due to tyrosine kinase activity. This modulatory mechanism ay 
play a role on the regulation of Ca 2÷ influx and uterine contraction during normal labor and preterm labor. 
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1. Introduction 
Voltage-dependent Ca2 + channels are known to play a 
key role in excitation-contraction coupling of uterine 
smooth muscle. Opening of the channels produces mem- 
brane depolarization and Ca 2+ entry that are needed for 
uterine contraction. Protein phosphorylation (on serine 
and/or  threonine groups) is a major regulatory process for 
the modulation of Ca 2÷ channels in neuronal cells [1], 
myocardial cells [2], and vascular smooth muscle cells 
[2,3]. In uterine smooth muscle cells, however, cAMP and 
cGMP (and their respective protein kinases) do not appear 
to modulate the activity of the L-type Ca 2÷ channels [4]. 
We found that protein kinase C, in contrast, does modulate 
the Ca 2+ channels: addition of phorbol esters increased the 
L-type Ca 2+ current (/Ca(L)) by 37% [5], and this stimula- 
tory action depended on intracellular Ca 2+ level (Kusaka, 
M. and Sperelakis, N., unpublished observations). To fur- 
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ther clarify the modulation of Ca 2+ channels in myome- 
trial cells, we wanted to examine the possible role of 
tyrosine-specific protein kinase. 
Tyrosine kinase has been shown to be correlated with 
the signal transduction for several growth factors, such as 
epidermal growth factor (EGF) [6,7], fibroblast growth 
factor (FGF) [8,9], platelet-derived growth factor (PDGF) 
[10,11]. The insulin receptor also has tyrosine kinase activ- 
ity [12]. However, only a few reports have been published 
about the regulation of ion channels, including Ca 2÷ chan- 
nels, by tyrosine kinase. In neuronal cells, basal FGF was 
reported to increase /Ca(L), but the participation of tyrosine 
kinase was not proposed [13,14]. Tyrosine kinase in- 
hibitors, such as genistein, were reported to block the 
Ca 2+ current in vascular smooth muscle cells [15], and to 
activate a non-selective cation channel [16]. However, no 
information is available for uterine smooth muscle. 
In this study, we investigated the possible modulation 
of the slow Ca 2+ channels in rat myometrial cells by 
studying the effect of tyrosine kinase inhibitors on /Ca(L) 
using the whole-cell patch clamp. We found that /Ca(L) is 
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inhibited by the tyrosine kinase inhibitor, genistein. Thus, 
endogenous tyrosine kinase activity may be involved in the 
regulation of Ca 2+ channel activity in myometrial cells, 
namely to exert tonic stimulation. 
Data are presented as means + S.E. Theoretical curves 
were fitted to the data with the least-squares method. 
2.3. Drugs 
2. Materials and methods 
2.1. Cell preparation 
Freshly-isolated single smooth muscle cells were pre- 
pared from the longitudinal layer of late pregnant (18-! 9 
day) rat (Sprague-Dawley, Zivic-Miller, USA) uterus as 
previously described [17]. The rat was anesthetized byCO 2 
and decapitated. Distal part of uterine horn was excised 
and the longitudinal layer was carefully isolated by remov- 
ing the endometrium and circular muscle layer under a 
binocular microscope. The tissues were cut into small 
pieces and incubated in nominally calcium-free solution 
containing (in mM) 140 NaCI, 6 KC1, 10 glucose, 10 
Hepes (pH 7.35) for 20 min and then with 0.2-0.3% 
collagenase (Worthington Biochemical Co., Freehold, NJ, 
USA) for 80 min at 37°C. After digestion, the tissues were 
rinsed twice and agitated in the fresh calcium-free solution. 
Cell suspension was stored at 4°C and used for experi- 
ments within 6 h after cell dispersion. Most of the obtained 
cells were spindle-shaped, 50-200 Izm long and 20-30 
/xm width, as previously reported [18]. 
2.2. Patch-clamp recording 
Whole-cell voltage clamp recording was carried out 
with a suction pipette and a patch clamp amplifier 
(Axopatch-lD, Axon Instruments, Foster City, USA) using 
standard techniques [19]. The patch electrodes (2-5 M/2) 
were made from borosilicate glass capillary tubing (World 
Precision Instruments, USA). The cell suspension was 
placed into a small chamber (0.2 ml) on the stage of an 
inverted microscope (TMD-Diaphoto, Nikon, Tokyo, 
Japan). To isolate the /Ca(C), the pipette was filled with 
high Cs + solution of the following composition (in mM): 
l l0 CsOH, 20 CsC1, 110 glutamic acid, 5.2 MgCI 2, 10 
Hepes, 5 Na2ATP, 10 EGTA (pH 7.2). The bath solution 
contained (in mM): 140 tetraethylammonium chloride, 2 
CaC12, 10 glucose, 10 Hepes, 3 4-aminopyridine (4-AP) 
(pH 7.35). Series resistance was partly (ca. 80%) compen- 
sated electrically. Leak current and residual capacitive 
current were subtracted using P/4  protocol. Current and 
voltage signals were filtered at 2 kHz and digitized by an 
A /D  converter (TL- i, Axon Instruments) and analyzed on 
an IBM-AT personal computer using the pCLAMP soft- 
ware (Axon Instruments). The membrane capacitance was 
determined from the current amplitude licited in response 
to a hyperpolarizing voltage ramp pulse of 0.2 V/s  from a 
holding potential of 0 mV to avoid interference by any 
time-dependent ionic currents, All experiments were car- 
ried out at room temperature (22-24°C). 
Genistein, daidzein and tyrphostin-A25 were obtained 
from Calbiochem-Novabiochem Corp. (San Diego, CA, 
USA). These agents were dissolved in dimethylsulfoxide 
(DMSO) for a stock solution, prepared in aliquots and 
frozen until use. Final maximal concentration of DMSO 
was 0.1% and had no effect on /Ca(L)" 
3. Results 
The mean membrane capacitance of uterine smooth 
muscle cells was 125.0 _+ 4.8 pF (n = 27) and was not 
affected by application of genistein or other drugs used in 
this study. Unless stated otherwise, the /Ca(L) was elicited 
by 300 ms depolarizing step pulses from a holding poten- 
tial (HP) of - 60 mV every 20 s, The study of the effect of 
genistein was started after the /Ca(L) became stabilized 
after breaking into the cell. The current was completely 
inhibited by 1 /.tM nifedipine (data not shown), and the 
kinetic properties including inactivation time course and 
current/voltage r lationship (see Fig. 1) were consistent 
with those of /ca(c) we reported previously for uterine 
smooth muscle cells [17,18]. 
Bath application of genistein (100 /zM) reduced Icate) 
by 44.7 +2.3% (n=8) .  Fig. 1A shows superimposed 
current races before (Aa) and 5 min after (Ab) genistein 
application. Note the marked inhibition of the peak inward 
current produced by genistein. The current/voltage r la- 
tionship for peak /Ca(L) was not significantly shifted by 
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Fig. 1. Effect of genistein on /Ca(L) in 19-day pregnant rat uterine smooth 
muscle cells. (A) Superimposed current races elicited by 300 ms depolar- 
izing pulses ( -50  mV to + 10 mV in 10 mV increments) from a holding 
potential (HP) of -60  mV, before and 5 min after bath application of 
100 /zM genistein. (B) Current/voltage r lationships of IC~(L) obtained 
before (open circles) and 5 rain after (closed circles) genistein applica- 
tion. The pipette solution contained Cs + to inhibit K + current and the 
bath solution contained 2 mM Ca 2+. Data were obtained from five cells, 
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Fig. 2. Time-course of the inhibition of IC~(L) by I00 /~M genistein. The 
effect reached the stable level within 5 min after application of genistein, 
was reversed by washout. Currents were elicited from a HP of -60  mV 
to a step potential of + 10 mV every 20 s. (Inset) Superimposed current 
traces showing the IC~(L) recorded before (a) and 6 rain after (b) 
application, and after washout (c) of genistein. 
genistein; there was no obvious change in voltages for 
threshold or peak current (Fig. 1B). 
Fig. 2 shows the time course of the effect of genistein 
in one representative experiment. /Ca(L) was  evoked by 
depolarizing pulses to + 10 mV (HP of -60  mV, every 20 
s), and a peak current amplitude was measured. The 
decrease in ICa(L) started within a few minutes after bath 
application of genistein and reached a stable level within 5 
min. The effect of genistein on /Ca(L) was almost com- 
pletely reversed by washout. 
Fig. 3 shows the dose/response curve for the inhibitory 
effect of genistein at a HP of -60  mV. Peak IC~(L) 
amplitude in the presence of genistein was plotted against 
the various concentrations of the drug as a percent of 
control. Data points were fitted to the Hill equation: 
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Fig. 3. The dose/response r lationship for genistein i hibition of /Ca(L)" 
Peak /Ca(L) amplitude was measured before and 5 rain after application of
various concentrations of genistein in the bath. Pulse protocol was the 
same as Fig. 2. Numbers in parentheses indicate the number of cells for 
each data points. The maximum inhibition, IC5o and I4ill coefficient (n H ) 
were 46%, 50 /xM and 3.7, respectively. 
T T 
Control Genistein 
1.0 - ; , ~  o • ~ - 
• - 
~ 0.5 
.~  mV 
60 mV 3110 ms mV Io0 rnv 3 s ~ . ~  
~...4J. • 'llt • .~.7"J,-.._. 0.0 
-100 -80 -60 -40 -20 0 20 40 
Membrane potential (mV) 
Fig. 4. The activation and inactivation curves for IC,(L) before and after 
genistein (100 /~M) application. Steady-state inactivation (h~) curves 
were obtained from five cells using a double-pulse protocol. Pre-condi- 
tioning pulses of 3 s duration were applied in 10 mV steps between 
- 100 mV and + 10 mV from a HP of -60  mV, and then the test pulse 
of 300 ms duration was applied to + 10 mV (interpnlse duration was 5 
ms). The inactivation curve in the presence of genistein shifted towards a 
negative potential by about 15 mV, as compared with the control. 
Activation curves were derived from the current/voltage r lationships 
obtained from five cells, and the voltage dependence was not changed by 
genistein. Inset shows the pulse protocol and experimental condition was 
the same as in Fig. 2. 
~genistein/ Icontrol (%)  = Emax/ ( l  + ([genistein]/ICs0)=H) + 1~-  Emax), where Ema x is the maximum inhibitory ef- 
fect, n H is the Hill coefficient, ICs0 is the concentration of 
the drug causing 50% of the maximal inhibitory effect. 
The n H value was 3.65 and the IC50 value was 49.9/xM. 
The maximum inhibitory effect was calculated to be 45.6%, 
and was almost attained at the concentration above 100 
/zM. 
To investigate the effects of genistein on the voltage 
dependence of activation and inactivation, steady-state ac- 
tivation and inactivation (h~) curves were obtained before 
and after genistein application (Fig. 4). Activation curves 
were derived from the current/voltage relationships (Fig. 
4, right inset). Conductance (G) was calculated from the 
equation: G = Ica / (Vm - Vrev), where /Ca is the peak cur- 
rent elicited by depolarizing test pulses to the various 
potentials, and V~e v is the reversal potential (+  60.6 ___ 1.3 
mV, n = 18; obtained from the extrapolated current/volt- 
age curves (see Fig. 1)). Gma x is the maximum Ca 2÷ 
conductance (calculated at potentials above + 10 mV). The 
points for G/Gma x were plotted against the membrane 
potential as a relative amplitude. These data were fitted to 
the Boltzmann equation: 1/(1 + exp((V m - Vl/2)/k)), 
where V m is the conditioning potential, V~/2 is the poten- 
tial required for half-activation of current, and k is the 
slope factor. V~/2 and k were -6 .7  mV and -7 .0  mV in 
control, and -4 .7  mV and -6 .0  mV (n - -5 )  after genis- 
tein application, respectively. There is no apparent differ- 
ence among these values. 
The h= curves were obtained by a double-pulse proto- 
col (Fig. 4, left inset). The peak current elicited by test 
pulses was normalized by the maximum current (evoked 
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Fig. 5. Lack of the effect of daidzein, an inactive genistein analog. Bath 
application of daidzein (300 /xM) did not affect /Ca(L)" Subsequent 
application of genistein (300 /zM) markedly reduced the current. Experi- 
mental condition was the same as in Fig. 2. (Inset) Superimposed current 
traces recorded uring the control period (a), in the presence of daidzein 
(b) and genistein (c). 
from a pre-pulse of -100 mV) and plotted against he 
conditioning potential. Resulting inactivation curves were 
also fitted to the Boltzmann equation. The values of VI/2 
(half-inhibition potential) and k were -31.9 mV and 9.0 
mV in control, -46.4 mV and 9.1 mV in the presence of 
genistein (n = 5). The inactivation curve was shifted in the 
negative direction by 14.5 mV, thereby suggesting that 
genistein has a voltage-dependent inhibitory action. 
In order to examine whether the effect of genistein on 
/Ca(L) was mediated by tyrosine kinase, experiments were 
performed using daidzein, which has similar structure to 
genistein but has no inhibitory effect on tyrosine kinase 
[20]. Bath application of 300 /xM daidzein did not affect 
~Ca(L) (Fig. 5). Subsequent application of genistein (300 
/zM) decreased the current. The peak JCa(L) measured at 5 
min after daidzein (300/xM) application was 96.7 _+ 1.1% 
of control (n = 4). 
We also tested the effect of tyrphostin-A25, another 
tyrosine kinase inhibitor that has a different structure. 
However, bath application of tyrphostin-A25 (100 ~M for 
10 min) did not affect /Ca(L) (peak /Ca(L) of 103.9 __+ 3.1% 
of control; n = 4, data not shown). 
4. Discuss ion 
In the present study, we found that a selective tyrosine 
kinase inhibitor, genistein, inhibits IC,(L) dose-dependently 
in freshly-isolated uterine smooth muscle cells obtained 
from late pregnant rat. The maximal inhibition was 46%, 
and the IC50 value was 50/xM. The onset of the inhibition 
of ICa(L) produced by genistein was fast (within a few 
minutes), and the effect could be quickly washed out. 
Genistein shifted the inactivation curve of ICatL) in the 
negative direction by 15 mV, whereas the activation curve 
was not affected. The genistein analog, daidzein, which is 
inactive as a tyrosine kinase inhibitor, did not produce a 
decrease of the current. These results suggest hat ICa(L )
inhibition by genistein may be mediated by inhibition of 
endogenous tyrosine kinase activity. 
The concentration range of genistein that affected /Ca(L) 
in this study (ICs0 = 50/xM) is comparable to that needed 
for the inhibition of tyrosine kinases [20,21]. The fact that 
the maximal inhibitory effect (46%) was not 100% might 
be explained by several possible mechanisms. Genistein 
may decrease ither single-channel conductance or open 
probability of the Ca 2+ channels to about the half of the 
normal level. Another possibility is that genistein may 
completely block the Ca 2 ÷ channels, but only a fraction of 
the channels are sensitive to the agent, i.e., are normally 
phosphorylated by tyrosine kinase. The Hill coefficient for 
the dose/response curve is 3.7 (see Fig. 3), suggesting that 
there may be multiple tyrosine kinase phosphorylation 
sites on the Ca 2÷ channels. 
Genistein shifts the steady-state inactivation curve to 
the left, indicating that the effect of genistein is voltage-de- 
pendent, and therefore should be more prominent when the 
membrane is held at depolarized potentials (see Fig. 4). 
The leftward shift of the steady-state inactivation curve 
may be one of the mechanisms of the inhibition of lCatL) 
by genistein, but is insufficient o account for the 46% 
inhibition; the predicted inhibitory effect due to the shift is 
ca. 15% at a HP of -60  mV (see Fig. 4). 
All of these findings suggest hat phosphorylation by 
tyrosine kinase regulates the basal activity of the L-type 
Ca 2+ channels in myometrial cells. Our findings are con- 
sistent with the reported block of Ica~L) in vascular smooth 
muscle cells [15]. The ICs0 value for the inhibitory effect 
of genistein (36 /xM) was similar to that in our study (50 
/zM). However, there are some differences between our 
findings and those in the previous report on vascular 
smooth muscle. In our study, genistein had the maximal 
inhibitory effect (ca. 50%) at a concentration f 100 /zM; 
i.e., 300 /xM did not produce greater inhibition. In con- 
trast, in vascular smooth muscle cells, genistein and tyr- 
phostin-23 completely blocked /Ca(L) at 300 /zM. One 
possible explanation for this difference is that the L-type 
Ca 2÷ channels in these two types of smooth muscles are 
regulated to different degrees by endogenous tyrosine ki- 
nases. 
Although genistein had significant inhibitory effect on 
Ica(C), another tyrosine kinase inhibitor, tyrphostin-A25, 
did not affect he current when added to the bath. The lack 
of the effect of tyrphostin-A25 could be due to its diffi- 
culty in penetrating through the cell membrane. It was 
reported that the onset of inhibitory effect of tyrphostin 
derivatives is slow and many hours of incubation is re- 
quired [22]. Alternatively, these two agents may act on 
different yrosine kinase isotypes. Myometrial cells may 
have an isotype of tyrosine kinase that is sensitive to 
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genistein, but not to tyrphostin-A25. The concentration of 
tyrphostin-A25 used in this study (100 /zM) was reported 
to be sufficient for the inhibition of tyrosine kinase activity 
of the EGF receptor (ICs0 = 15 /zM) [23]. 
The possibility of a direct blocking action of genistein 
on the Ca 2+ channels can not be excluded. For example, 
the rapid onset of the effect of genistein and the rapid 
offset (washout recovery) are consistent with a direct 
action on the outer surface of the channel. In addition, both 
active and inactive tyrphostin derivatives had similar po- 
tent inhibitory effects on /Ca(L) in vascular smooth muscle 
cells [15]; this provides evidence for a direct action of 
these agents on the Ca 2+ channel proteins. One argument 
against a direct action on the channel itself is that the 
maximum degree of inhibition of lCa~L) was only to about 
50% (Fig. 3); if the site of action was on the channel 
protein, one would expect 100% inhibition to be attained at 
high dose, unless there were two types of Ca 2+ channels. 
A physiological role of tyrosine kinase in the modula- 
tion of L-type Ca 2+ channels by in myometrial cells is a 
distinct possibility. The inhibition of /Ca(L) by genistein 
suggests that tyrosine phosphorylation stimulates the basal 
activity of the Ca 2+ channels in myometrial cells. Since 
tyrosine kinase may be anchored to receptors imbedded in 
the cell membrane, this enzyme is unlikely to be lost from 
the cytosol after breaking into the cell, and therefore 
rundown of /Ca(L) should not occur during whole-cell 
recording. Because the L-type Ca ~-+ channels play an 
important role in Ca 2+ influx and thereby uterine contrac- 
tion, the phosphorylation of the channels by tyrosine ki- 
nase could affect normal labor and preterm labor. For 
example, it was reported that angiotensin II, which is 
known to augment uterine contraction, stimulates tyrosine 
phosphorylation i  vascular smooth muscle cells [24]. Al- 
though angiotensin II did not increase /Ca<L) in myometrial 
cells (Kusaka, M. and Sperelakis, N., unpublished observa- 
tions), it is possible that, because the hormone induces 
Ca 2+ release from SR, the resulting increase in intra- 
cellular Ca 2+ may inhibit the Ca 2+ channels. In neuronal 
cells, basic FGF, whose actions are known to be associated 
with tyrosine kinase, was reported to increase IC~(L) [13,14]. 
These findings support a possible role of tyrosine kinase in 
agonist-induced contraction of uterine muscle. 
In conclusion, genistein inhibits IC~<L) in uterine smooth 
muscle cells. This effect may be mediated by inhibition of 
tyrosine kinase, but a direct action on the Ca 2+ channels 
cannot be excluded. Possible modulation of the L-type 
Ca 2+ channels by tyrosine kinase could contribute to the 
regulation of basal and agonist-induced contractility of 
uterine muscle during pregnancy. 
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